Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Eli Lilly and Company

LLY Pharmaceuticals Unknown Updated July 11, 2026
$1,188.57
52W $623.78 – $1249.45
63/100
$1.15T
45.5
0.50
Price History (6M)
AI Committee Verdict
Buy
Conviction: Contested · 50% agreement · 6 analysts
-16.4%
100%
Executive Summary
6 analysts weighed in with 50% agreement on a bullish lean. Growth Analyst: 4 consecutive earnings beats -- consistent execution. Risk Analyst: Bollinger bandwidth of 16.5% signals elevated volatility. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
  • Daily trend: uptrend.
  • Weekly trend: uptrend.
  • Daily and weekly trends are both bullish — multi-timeframe alignment, highest confidence.
  • Higher Highs / Higher Lows structure confirms bullish price action.
  • Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
  • MACD histogram is negative (-0.874) — bearish momentum.
AI Investment Committee
Committee Consensus As of July 11, 2026
Overall Committee Score
63/100
Agreement
50%
Analysts
6
Conviction
Contested
Growth Analyst bullish
82 / 100 · Moderate confidence
Strong, accelerating growth with consistent execution
+ 4 consecutive earnings beats -- consistent execution
Technical Analyst neutral
57 / 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 16.5% signals elevated volatility
Macro Analyst bullish
70 / 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst neutral
58 / 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager bullish
75 / 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Open Full Terminal →
Technical Analysis
RSI (14)
51.0
Neutral
MACD Histogram
-0.874
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.62
Inside Bands
Price vs Moving Averages
EMA 9
$1,198.54 Below
EMA 21
$1,167.75 Above
EMA 50
$1,106.25 Above
EMA 200
$996.67 Above
Fundamental Analysis
Valuation
0
Growth
93
Profitability
100
Financial Health
55
Valuation
P/E Ratio 45.5×
P/B Ratio 38.29×
PEG Ratio
Dividend Yield 0.57%
52W High $1249.45
52W Low $623.78
Quality & Growth
ROE 10131.0%
ROA 2273.0%
Gross Margin 8283.0%
Operating Margin 4363.0%
Revenue Growth YoY +4744.0%
Debt / Equity 1.60
AI Fundamental Assessment
P/E ratio of 45.5 (rich relative to a 15-40x range); Price-to-book of 38.3x; Revenue growth (YoY) of 47.4%; EPS growth (YoY) of 128.8%; Return on equity of 101.3%; Return on assets of 22.7%; Net margin of 35.0%; Gross margin of 82.8%; Current ratio of 1.58 (healthy short-term liquidity); Debt-to-equity of 1.60; Most recent quarter beat estimates by 27.0%; 4 consecutive earnings beats; EPS growth accelerating (+7.4% -> +13.4% QoQ); Analyst estimates rising over recent quarters
Key Risks
  • MACD histogram is negative (-0.874) — bearish momentum.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full LLY Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal → Mobile
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime